Vitreous Floaters Clinical Trial
Official title:
Low Dose Atropine For Symptomatic Vitreous Floaters
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01970267 -
Clear Vision Study
|
N/A |